INTERLEUKIN-18 AND EMPHYSEMA IN  CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Angjela Debreshlioska; Milena Miletic Gjoreska; Marija Kostoska; Meri Kirijas; Kristijan Jovanovski

Angjela Debreshlioska University Clinic of Pulmonology and Allergology, Skopje, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
Milena Miletic Gjoreska University clinic of pulmonology and allergology, Skopje, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
Marija Kostoska University clinic of pulmonology and allergology, Skopje, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
Meri Kirijas Institute of Immunobiology and Human Genetics, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
Kristijan Jovanovski Resident et University clinic of pulmonology and allergology, Skopje, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases. Emphysema involves the destruction of alveolar walls, resulting in diminished gas exchange and airflow constraint. Interleukin-18 (IL-18), a potent pro-inflammatory cytokine, plays a pivotal role in the immune response and inflammation regulation, implicated in various autoimmune and inflammatory diseases. Elevated IL-18 levels have been noted in emphysema patients, contributing to chronic inflammation, tissue damage, and airway remodeling. Aim: The aim of this study was to determine IL-18 values in patients with emphysema, compare their values in patients with different stages of the disease, and analyze their correlation with inflammatory and clinical parameters. Materials and Methods: This cross-sectional study was conducted at the University Hospital of Pulmonology and Allergology in Skopje, involving 30 COPD patients, randomly sampled, meeting specified inclusion and exclusion criteria. Signed informed consent was obtained from all participants. Data on demographic, clinical, and smoking history were obtained from medical records. Spirometry and imaging techniques were performed for lung function and emphysema assessment. Blood samples were collected for inflammatory parameters measurement and IL-18 concentration measurement using Luminex technology. The study included 30 COPD patients (10 women, 20 men), with an average age of 65.2 years, all of whom were smokers. Emphysema was present in 26 patients (86.5%): 11 with mild, 10 with moderate, and 5 with severe emphysema. Average age increased with severity: 52.3 years (no emphysema), 61.5 (mild), 66.4 (moderate), and 65.6 (severe). Cough prevalence was 75% (no emphysema) to 81.2% (mild) and 80% (moderate and severe). Dyspnea rose from 50% (no emphysema) to 100% (severe). Chest pain occurred in 80% of severe cases. FEV1 values decreased with severity: 64.5% (no emphysema), 60.3% (mild), 47.5% (moderate), and 37.2% (severe). Inflammatory parameters (leukocyte and neutrophil counts) did not vary by emphysema severity, but IL-18 levels significantly correlated with severity. In correlation analysis, higher IL-18 levels were associated with emphysema severity and decline in lung function (FEV1), while no significant correlations were found between IL-18 and age, chest pain, dyspnea, cough, or leukocyte counts. These findings highlight the potential utility of IL-18 as a biomarker in emphysema management and emphasize the need for further research to elucidate its therapeutic implications.

Keywords: COPD, emphysema, Interleukin–18.

References

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2024 report. https://goldcopd.org/2024-goldreport/(Accessed Oct 2024).
2. Forey BA, Thornton AJ, Lee PN. Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema. BMC Pulm Med 2011;11:36.
3. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses.
Annu Rev Immunol 2001;19:423–474.
4. Shimizu M, Takei S, Mori M, Yachie A. Pathogenic roles and diagnostic utility of interleukin-18 in autoinflammatory diseases. Front Immunol. 2022 Sep 22;13:951535.
5. Imaoka H, Hoshino T, Takei S, Kinoshita T, Okamoto M et al. Interleukin-18 production and pulmonary function in COPD. Eur Respir J. 2008 Feb;31(2):287-97.
6. Kubysheva N, Boldina M, Eliseeva T, Soodaeva S, Klimanov I et al. Relationship of Serum Levels of IL-
17, IL-18, TNF-alpha, and Lung Function Parameters in Patients with COPD, Asthma-COPD Overlap, and
Bronchial Asthma. Mediators Inflamm. 2020 Jul 12;2020:4652898.
7. Wang J, Liu X, Xie M, Xie J, Xiong W, Xu Y. Increased expression of interleukin-18 and its receptor in
peripheral blood of patients with chronic obstructive pulmonary disease. COPD: Journal of Chronic
Obstructive Pulmonary Disease. 2012 Jul 26;9(4):375-81.
8. Hoshino T, Kawase Y, Okamoto M, Yokota K, Yoshino K et al. Cutting edge: IL-18-transgenic mice: in
vivo evidence of a broad role for IL-18 in modulating immune function. The Journal of Immunology. 2001
Jun 15;166(12):7014-8.
9. Uwagboe I, Adcock IM, Lo Bello F, Caramori G, Mumby S. New drugs under development for COPD. Minerva Med. 2022 Jun;113(3):471-496
10. Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88.
11. Lynch DA, Austin JH, Hogg JC, Grenier PA, Kauczor HU et al. CT-Definable Subtypes of Chronic Obstructive Pulmonary Disease: A Statement of the Fleischner Society. Radiology. 2015 Oct;277(1):192-205.
12. Kitasato Y, Hoshino T, Okamoto M, et al. Enhanced expression of interleukin-18 and its receptor in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2004;31:619–625
13. Freeman CM, Han MK, Martinez FJ, Murray S, Liu LX et al. Cytotoxic potential of lung CD8+ T cells increases with chronic obstructive pulmonary disease severity and with in vitro stimulation by IL-18 or IL- 15. The Journal of Immunology. 2010 Jun 1;184(11):6504-13.
14. Ntritsos G, Franek J, Belbasis L, Christou MA, Markozannes G et al. Gender-specific estimates of COPD prevalence: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018 May 10;13:1507-1514.
15. Varmaghani M, Dehghani M, Heidari E, Sharifi F, Moghaddam SS et al. Global prevalence of chronic obstructive pulmonary disease: systematic review and meta-analysis. East Mediterr Health J. 2019 Mar 19;25(1):47-57.
16. Kumbhare S, Pleasants R, Ohar JA, Strange C. Characteristics and Prevalence of Asthma/Chronic Obstructive Pulmonary Disease Overlap in the United States. Ann Am Thorac Soc. 2016 Jun;13(6):803-10.
17. Martini K, Frauenfelder T. Advances in imaging for lung emphysema. Annals of Translational Medicine. 2020 Nov;8(21).